Huason Pharmaceutical: Holding subsidiarys Class 1 new drug has received clinical trial approval, involving 2 indications and 6 specifications.

Huason Pharmaceutical announced that its holding subsidiary Chengdu Huason Aori Pharmaceutical Co., Ltd. has received the "Drug Clinical Trial Approval Notice" approved by the National Medical Products Administration for the phosphate ORIC-1327 eye drops, corresponding to two indications with a total of six specifications. This drug is a Class 1 new drug, indicated for glaucoma and ocular hypertension, and independently developed by Huason Aori. Phosphate ORIC-1327 eye drops are the second Class 1 new drug project to gain approval for clinical trials from Huason Aori. As of the date of this announcement, the company's subsidiary Chongqing Huason Yingnuo Biotechnology Co., Ltd. and Huason Aori have collectively obtained clinical approvals for three Class 1 new drug projects.